|
|
| Line 1: |
Line 1: |
| | |
| | == Historic Reference == |
|
| |
|
| Arch Environ Health. 1962 Aug;5:100-5. Thalidomide embryopathy. | | Arch Environ Health. 1962 Aug;5:100-5. Thalidomide embryopathy. |
| Line 6: |
Line 8: |
| http://www.ncbi.nlm.nih.gov/pubmed/14464040 | | http://www.ncbi.nlm.nih.gov/pubmed/14464040 |
|
| |
|
| ==PubMed Bookshelf==
| |
|
| |
| ===Clinical Methods===
| |
| NCBI » Bookshelf » Clinical Methods » The Cardiovascular System » Family History of Heart Disease
| |
|
| |
| http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=cm&part=A540#A546
| |
| Family History of Heart Disease - thalidomide (tetralogy, VSD, ASD, truncus arteriosus),
| |
|
| |
| ===Developmental Biology===
| |
| * http://www.ncbi.nlm.nih.gov/sites/entrez?db=books&doptcmdl=DocSum&term=Thalidomide+AND+dbio%5Bbook%5D
| |
| * Table 21.2. Some agents thought to cause disruptions in human fetal developmenthttp://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=dbio&part=A5173&rendertype=table&id=A5176
| |
|
| |
| ==Thalidomide Metabolites in Mice and Patients with Multiple Myeloma==
| |
|
| |
| http://www.ncbi.nlm.nih.gov/pubmed/12738721
| |
|
| |
| "Our results show that thalidomide metabolite profiles in multiple myeloma patients differ considerably from those in mice. The lack of measurable hydroxylated metabolites in urine and in 1 case plasma of these patients suggests that such metabolites are not responsible for the therapeutic effects of thalidomide in multiple myeloma. We suggest that thalidomide may act directly, down-regulating growth factors essential for multiple myeloma growth."
| |
|
| |
|
| |
|
| |
| http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0020061
| |
|
| |
| Box 1. Poisoning following Widespread Environmental Contamination from Commercial Toxins
| |
| Lead: One hundred years ago, an epidemic of lead poisoning was described among children who ingested leaded house paint [2,3]. The children developed anemia, encephalopathy, paralysis, and blindness.
| |
|
| |
| Methyl Mercury: In the 1950s, in the Japanese fishing village Minamata Bay, which was contaminated with methyl mercury, children developed cerebral palsy, limb defects, and mental retardation [4].
| |
|
| |
| PCBs: In Taiwan and Japan during the 1960s and 1970s, the ingestion of PCB-contaminated rice bran oil by pregnant women led to fetal wasting and cola-colored, dull, apathetic children [5].
| |
|
| |
| Tobacco: During the past century, widespread tobacco use has led to an epidemic of undersized, premature babies and children with repeated bouts of wheezing or asthma [6,7,8,9,10].
| |
|
| |
| ----
| |
|
| |
|
| |
|
| |
| http://www.tga.gov.au/committee/acpm.htm
| |
|
| |
| In 2010, ADEC was replaced by the Advisory Committee on Prescription Medicines (ACPM).
| |
|
| |
| The Advisory Committee on Prescription Medicines (ACPM) was formed in January 2010. The ACPM advises and makes recommendations to the TGA on prescription medicines. This includes:
| |
|
| |
| inclusion of a prescription medicine on the Australian Register of Therapeutic Goods (the Register)
| |
| changes to an entry of a prescription medicine on the Register
| |
| removal or retention of a prescription medicine on the Register.
| |
|
| |
|
| |
|
| |
| Australian Drug Evaluation Committee was established in 1963 following the Thalidomide experience.
| |
|
| |
|
| |
| [http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=18418038 Knobloch J, Rüther U.] Shedding light on an old mystery: Thalidomide suppresses survival pathways to induce limb defects. Cell Cycle. 2008 Feb 14;7(9)
| |
|
| |
| "Many hypotheses have been proposed to explain the molecular mechanism of thalidomide teratogenicity, in particular regarding to limb defects. Most experimental evidence in vivo has been provided for a model that suggests the generation of oxidative stress by thalidomide with subsequent down-regulation of Wnt and Akt survival pathways. ...We extend this model by presenting new data demonstrating an involvement of the transcription factors Tbx5 and Sall4 in thalidomide-induced molecular pathology."
| |
|
| |
| [http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17213509 Benegbi M.] 45 years later...where do we stand? Can J Clin Pharmacol. 2007 Winter;14(1):e37-9.
| |
|
| |
| [http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16505120 Li PK, Pandit B, Sackett DL, Hu Z, Zink J, Zhi J, Freeman D, Robey RW, Werbovetz K, Lewis A, Li C.] A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol Cancer Ther. 2006 Feb;5(2):450-6.
| |
|
| |
| == Chemotherapy ==
| |
| == References == | | == References == |
| ===Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).=== | | ===Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).=== |
| Line 83: |
Line 26: |
| PMID: 18418038 | | PMID: 18418038 |
|
| |
|
| == Books on Thalidomide == | | [http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17213509 Benegbi M.] 45 years later...where do we stand? Can J Clin Pharmacol. 2007 Winter;14(1):e37-9. |
| A selection of recent general public information books on Thalidomide, available from various internet commercial suppliers (search using the book title). Please note that this listing does not reflect an endorsement of the book or its content and is provided for educational purposes only.
| |
| | |
| '''Thalidomide Kid''' (Paperback) by Kate, Rigby (Author)
| |
| | |
| '''Thalidomide - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References''' (Paperback) by ICON Health Publications (Author)
| |
|
| |
|
| Internet supplier link: [http://amazon.com/ Amazon]
| | [http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16505120 Li PK, Pandit B, Sackett DL, Hu Z, Zink J, Zhi J, Freeman D, Robey RW, Werbovetz K, Lewis A, Li C.] A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol Cancer Ther. 2006 Feb;5(2):450-6. |
Historic Reference
Arch Environ Health. 1962 Aug;5:100-5. Thalidomide embryopathy.
LENZ W, KNAPP K.
PMID: 14464040 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/pubmed/14464040
References
Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).
Rafiee P, Stein DJ, Nelson VM, Otterson MF, Shaker R, Binion DG.
Am J Physiol Gastrointest Liver Physiol. 2010 Feb;298(2):G167-76. Epub 2009 Nov 19.
PMID: 19926820
Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects.
Cell Cycle. 2008 May 1;7(9):1121-7. Epub 2008 Feb 14.
Knobloch J, Rüther U.
Institute for Animal Developmental and Molecular Biology, Heinrich-Heine-University, Düsseldorf, Germany. juergen.knobloch@uk-koeln.de
Abstract
Many hypotheses have been proposed to explain the molecular mechanism of thalidomide teratogenicity, in particular regarding to limb defects. Most experimental evidence in vivo has been provided for a model that suggests the generation of oxidative stress by thalidomide with subsequent downregulation of Wnt and Akt survival pathways. As a consequence apoptosis is induced during early embryonic limb development resulting in limb truncations. Here we summarize and discuss the relevant data supporting this hypothesis. We extend this model by presenting new data demonstrating an involvement of the transcription factors Tbx5 and Sall4 in thalidomide-induced molecular pathology. Finally, we discuss a possible participation of other stress-responsive and/or pro-apoptotic transcription factors in the mechanism of thalidomide teratogenicity.
PMID: 18418038
Benegbi M. 45 years later...where do we stand? Can J Clin Pharmacol. 2007 Winter;14(1):e37-9.
Li PK, Pandit B, Sackett DL, Hu Z, Zink J, Zhi J, Freeman D, Robey RW, Werbovetz K, Lewis A, Li C. A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol Cancer Ther. 2006 Feb;5(2):450-6.